Analyzing Biogen (BIIB) & Its Competitors
Biogen (NASDAQ: BIIB) is one of 45 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Biogen to similar companies based on the strength of its risk, profitability, institutional ownership, earnings, valuation, analyst recommendations and dividends.
Risk & Volatility
Biogen has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Biogen’s rivals have a beta of 1.28, indicating that their average stock price is 28% more volatile than the S&P 500.
Valuation and Earnings
This table compares Biogen and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Biogen||$11.72 billion||$6.42 billion||21.46|
|Biogen Competitors||$579.30 million||$241.72 million||-6.57|
Biogen has higher revenue and earnings than its rivals. Biogen is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
87.7% of Biogen shares are held by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares Biogen and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations and price targets for Biogen and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Biogen currently has a consensus price target of $332.00, suggesting a potential upside of 1.60%. As a group, “Biopharmaceuticals” companies have a potential upside of 7.59%. Given Biogen’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Biogen has less favorable growth aspects than its rivals.
Biogen beats its rivals on 7 of the 13 factors compared.
Biogen Company Profile
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company’s product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.